Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Jnj-37822681. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 1/20 | 1.00 |
| ▸ | DRD3 | P35462 | 2/20 | 1.00 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | DRD4 | P21917 | 2/20 | 0.41 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.41 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 3/20 | 0.41 |
| ▸ | JAK1 | P23458 | 3/20 | 0.41 |
| ▸ | TYK2 | P29597 | 3/20 | 0.41 |
| ▸ | JAK3 | P52333 | 3/20 | 0.41 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.39 |
| ▸ | CCR2 | P41597 | 1/20 | 0.39 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Jnj-37822681 SCHEMBL1022639 | 1.00 | DRD3 (1.00) | DRD3DRD2SIGMAR1ACHEALDH1A1 | |
| Jnj-37822681 SCHEMBL30349143 | 1.00 | DRD3 (1.00) | DRD3DRD2SIGMAR1ACHEALDH1A1 | |
| SCHEMBL5001494 | 0.90 | DRD2 (0.82) | DRD3DRD2ACHEMCHR1KDM4E | |
| SCHEMBL4995640 | 0.90 | DRD2 (0.82) | DRD3DRD2SIGMAR1ACHEDRD4 | |
| SCHEMBL1022610 | 0.90 | DRD2 (0.82) | DRD3DRD2SIGMAR1ACHEMCHR1 | |
| SCHEMBL1024284 | 0.88 | DRD2 (0.78) | DRD3DRD2SIGMAR1ACHEDRD4 | |
| SCHEMBL31635706 | 0.87 | DRD2 (0.78) | DRD3DRD2SIGMAR1ACHEDRD4 | |
| SCHEMBL1022190 | 0.87 | DRD2 (0.78) | DRD3DRD2SIGMAR1ACHEHTT | |
| SCHEMBL1020863 | 0.87 | DRD2 (0.78) | DRD3DRD2SIGMAR1ACHEDRD4 | |
| SCHEMBL4997907 | 0.86 | DRD2 (0.76) | DRD3DRD2SIGMAR1ACHEKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4178948-A2 | FUNCTIONALIZED ISONITRILES AND PRODUCTS, PREPARATION AND USES THEREOF | Universidade de Santiago de Compostela (ES) | 2023-05-17 | — | — | EP | claimed |
| US-12454520-B2 | Protein degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2025-10-28 | — | — | US | disclosed |
| US-20250214969-A1 | PROTEIN DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-07-03 | — | — | US | disclosed |
| WO-2025133292-A1 | POTASSIUM CHANNEL ACTIVATORS AND THEIR USE IN TREATING DISORDERS INVOLVING HYPEREXCITABILITY | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (DE) | 2025-06-26 | — | — | WO | disclosed |
| EP-4574152-A1 | POTASSIUM CHANNEL ACTIVATORS FOR USE IN THE TREATMENT OF EPILEPTIC DISORDERS | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (DE) | 2025-06-25 | — | — | EP | disclosed |
| US-12006329-B2 | Protein degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2024-06-11 | — | — | US | disclosed |
| EP-4364732-A2 | FUNCTIONALIZED ISONITRILES AND PRODUCTS, PREPARATION AND USES THEREOF | Universidade de Santiago de Compostela (ES) | 2024-05-08 | — | — | EP | disclosed |
| US-20240065999-A1 | Ophthalmic Formulation Containing a Dopaminergic Prodrug that may be Combined with One or More Agents | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2024-02-29 | — | — | US | disclosed |
| US-20230271983-A1 | FUNCTIONALIZED ISONITRILES AND PRODUCTS, PREPARATION AND USES THEREOF | UNIVERSIDADE DE SANTIAGO DE COMPOSTELA (ES) | 2023-08-31 | — | — | US | disclosed |
| EP-4178948-A2 | FUNCTIONALIZED ISONITRILES AND PRODUCTS, PREPARATION AND USES THEREOF | Universidade de Santiago de Compostela (ES) | 2023-05-17 | — | — | EP | disclosed |
| US-11623932-B2 | Protein degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-04-11 | — | — | US | disclosed |
| US-20220244263-A1 | METHODS FOR TREATING SMALL CELL NEUROENDOCRINE AND RELATED CANCERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-08-04 | — | — | US | disclosed |
| WO-2022099195-A1 | OPHTHALMIC FORMULATION CONTAINING A DOPAMINERGIC PRODRUG THAT MAY BE COMBINED WITH ONE OR MORE AGENTS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2022-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12006329-B2 | Protein degraders and uses thereof | MDM2, CUL1, PSMG3 | DRD2 4552/4885DRD3 4576/4885SIGMAR1 3735/4885 |
| US-20240065999-A1 | Ophthalmic Formulation Containing a Dopaminergic Prodrug that may be Combined with One or More Agents | SLC6A3, SLC18A2, SLC6A2 | DRD2 19/4885DRD3 78/4885SIGMAR1 63/4885 |
| US-12454520-B2 | Protein degraders and uses thereof | MDM2, CUL1, PSMG3 | DRD2 4552/4885DRD3 4576/4885SIGMAR1 3735/4885 |
| US-20230271983-A1 | FUNCTIONALIZED ISONITRILES AND PRODUCTS, PREPARATION AND USES THEREOF | KIT, MACF1, IK | DRD2 1689/4885DRD3 2307/4885SIGMAR1 517/4885 |
| US-11623932-B2 | Protein degraders and uses thereof | MDM2, CUL1, PSMG3 | DRD2 4552/4885DRD3 4576/4885SIGMAR1 3735/4885 |
| US-20250214969-A1 | PROTEIN DEGRADERS AND USES THEREOF | MDM2, CUL1, PSMG3 | DRD2 4552/4885DRD3 4576/4885SIGMAR1 3735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.